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ABSTRACT 
Background: Acinetobacter baumannii (A. baumannii) is emerging as one of the 
pathogens causing sepsis in neonates. Prevalence, antibiotic susceptibilities and case-
fatality rate (CFR) of A. baumannii in the neonatal units are not well known.  
Objective: To determine the prevalence, antibiotic susceptibility patterns and CFR of A. 
baumannii infection in neonates.   
Methods: Medical records of neonates admitted to Chris Hani Baragwanath Academic 
Hospital from 1st October 2007 to 31st October 2011 with a positive blood or cerebrospinal 
fluid culture due to A. baumannii were reviewed for demographic characteristics, clinical 
presentation, laboratory findings, antibiotic susceptibility and outcome.    
Results: There were 399 isolates of A. baumannii, with a prevalence of 4.3/1000 live 
births or 2/ 1000 patient-days, and accounting for 13% of all bacterial and fungal isolates. 
Antimicrobial susceptibility results were available for 379 isolates and only 155 medical 
records could be retrieved for analysis. The mean gestational age and birth weight of 
infected neonates was 30 weeks and 1400 grams respectively. Thirty seven (24%) were 
isolated from neonates with early onset sepsis and 118 (76%) from those with late onset 
sepsis. Sixty four percent of isolates were susceptible to Cephalosporins, 21% to 
Aminoglycosides and 17% were multi-drug resistant (MDR) isolates. The CFR was 32%. 
Factors associated with mortality were presence of a central venous catheter prior to onset 
of sepsis (49% vs 31%, p=0.03); need for ventilatory support (62% vs 36%, p=0.005) and 
inotropic support (57% vs 17%, p<0.001).  
Conclusions: A. baumannii is a common pathogen causing sepsis in neonates, with 17% of 
them being MDR. It is associated with high CFR. These findings highlight the need for 
strict enforcement of infection control and antibiotic stewardship practices. 
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MAIN RESEARCH REPORT 
1.0 INTRODUCTION 
Neonatal mortality rates in developing countries have been reported to be as high as 40-50 
per 1000 live births.1 Of these, infections are one of the major contributors, accounting for 
up to 56% of hospital deaths.2 In South Africa perinatal conditions account for up to 31% 
of infant mortality rates, of which 7% have been attributed to infections.3 Infections in 
neonates can either be acquired from the mother or from the hospital. Organisms causing 
infections within the first 72 hours of life are often acquired from the mother. Neonatal 
nosocomial infections refer to infections in the newborn that are hospital-acquired and 
usually occurring after the first 72 hours of life.4Premature neonates are at high risk of 
infection due to their underdeveloped innate immunity, fragile skin and lack of protective 
maternal antibodies. The increasing survival rate of these premature babies in neonatal 
units has led to an increase in duration of hospital stay, rendering them more susceptible to 
nosocomial infections. The National Institutes of Child Health and Human Development 
(NICHD) Neonatal Research Network reported on a cohort of 6215 very-low-birth-weight 
infants (401-1500 grams) 5, that 21% of these infants developed late-onset or nosocomial 
neonatal sepsis, of which 18% were caused by gram-negative bacteria. Infection was 
inversely proportional to birth weight and gestational age. Infants who developed late-
onset neonatal sepsis were found to have prolonged hospital stay. Overall mortality was 
reported to be as high as 18%, especially in babies infected with gram-negative bacteria. 
Other studies have quoted the incidence of nosocomial infections ranging from 7%-24%.5, 
6, 7  In a recent large cohort study of babies admitted to a neonatal intensive care unit, 
14.2% developed late-onset neonatal sepsis, with an overall mortality of 12.6%. Gram 
negative sepsis accounted for 10.4% of the sepsis attributable mortality.8 Nosocomial 
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infections have also been shown to increase the risk of neuro-developmental and growth 
impairment.9, 10  
 
Among the gram-negative bacteria causing infections, Acinetobacter baumannii has 
recently emerged as a leading nosocomial pathogen responsible for numerous hospital 
outbreaks over the past decade.11-13   In a recent cohort, gram negative bacilli accounted for 
32.6% of the late-onset neonatal infections, of which Acinetobacter baumannii accounted 
for 4.2%.8 Acinetobacter baumannii are aerobic gram-negative cocco-bacilli, belonging to 
the larger family of Acinetobacter species.14 These organisms have been recovered from 
soil, water, animals and humans. They are normal inhabitants of human skin, which in turn 
could be the major source of severe infections.15 In addition, various studies have shown 
the ability of Acinetobacter baumannii to survive in the hospital environment for prolonged 
periods, potentially playing a role in transmission of the organism during outbreaks. 
Sources have been shown to include reusable medical equipment, mattresses and gloves.16-
19  
 
The main concern with Acinetobacter baumanni is its ability to accumulate mechanisms of 
antimicrobial resistance rapidly, leading to multi-drug resistance. Acinetobacter baumanni 
has been shown to have acquired resistance to various classes of antimicrobials including 
Penicillin’s, Aminoglycosides, first, second and third generation Cephalosporins and more 
recently, Fluoroquinolones and Carbapenems. 12, 13, 20, 21, 22 Antibiotics that Acinetobacter 
baumannii has not developed resistance against so far are the Polymyxins (Colistimethate 
sodium/ Colistin). The most common mechanism of resistance to β-lactam antibiotics is 
the ability of the organism to produce β-lactamases. Other mechanisms of resistance 
include chromosomal mutations as well as loss of specific outer membrane proteins 
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responsible for influx of antibiotics into the cell.14 The main sites of infection include the 
respiratory tract, urinary tract, bloodstream, wounds and burns.21 Risk factors identified for 
the development of Acinetobacter baumannii infection include prematurity, very-low-
birth-weight, age < 7 days, mechanical ventilation, use of central venous catheters, as well 
as prior broad spectrum antibiotic use.12, 13 The mortality rates associated with 
Acinetobacter baumannii infections in neonates range from 14% to 80%. 12, 13, 23 A South 
African study reported a mortality rate of 22% .19 
 
In the neonatal unit at Chris Hani Baragwanath Academic Hospital (CHBAH) we have 
seen a high number of infants with positive cultures from normally sterile sites with 
isolates of Acinetobacter baumannii over the last few years. There also have been 
outbreaks due to this organism. The mortality due to Acinetobacter baumannii seems to 
vary during the different outbreaks and reasons for this are not clear. Possible reasons for 
this variation in mortality might include changes in antibiotic susceptibility, severity of 
illness or virulence of the organism and underlying problems in the infected patients. 
Therefore the objectives of this study were to determine characteristics of patients with 
positive culture from sterile sites due to Acinetobacter baumannii, its antibiotic 
susceptibilities, case fatality rates and factors associated with mortality. The approval to 
conduct this study was obtained from the University of Witwatersrand Human Research 
Ethics Committee, and CHBAH. 
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2.0 METHODS 
2.1 Study design: This is a retrospective descriptive study.   
 
2.2 Study population: The study sample included all babies admitted in the neonatal unit 
at CHBAH with culture confirmed Acinetobacter baumannii, from blood and/ or 
cerebrospinal fluid, during the study period 1st October 2007 to 31st October 2011. 
 
2.3 Study procedures: Names and hospital numbers of babies who were infected with 
Acinetobacter baumannii were obtained from the microbiology department register. These 
were used to retrieve hospital bed-letters from the neonatal department filing room. Data 
obtained from these bed-letters were entered into a computerized database for analysis. A 
case of Acinetobacter baumannii sepsis was defined as a neonate with confirmed culture 
positive with Acinetobacter baumannii from one or more normally sterile sites. Sites that 
were considered normally sterile were blood and cerebrospinal fluid. Multiple blood 
cultures yielding the same organism from the same patient within 72 hours of each other 
was considered to be a single infection. Antibiotic susceptibilities of Acinetobacter 
baumannii isolates were retrieved from the laboratory database. Acinetobacter baumannii 
was defined as multi-drug resistant (MDR) when the organism was resistant to all 
antibiotics except the Polymyxins. Patient’s demographics, clinical management, 
laboratory findings, and antibiotic susceptibilities were compared between those who died 
and those who survived. 
 
 2.3.1 Data Collection: Information collected included prenatal factors such as patient 
demographics and maternal human immunodeficiency virus (HIV) status. Postnatal factors 
obtained included birth weight and age of the baby at the onset of Acinetobacter baumannii 
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sepsis, use of central venous catheters, total parenteral nutrition and antibiotics prior to the 
onset of sepsis, any surgical/ invasive procedures underwent prior to the onset of sepsis, 
need for mechanical ventilation, duration of ventilation, need for inotropic support, length 
of hospital stay as well as death or survival within 7 days of diagnosis of the infection. 
Clinical signs, laboratory findings namely full blood count, C-reactive protein (CRP) and 
cerebrospinal fluid chemistry and cell count at the time of diagnosis of sepsis were also 
collected. Data were captured onto Microsoft® Office Excel® 2010  
 
2.3.2. Data analysis: Statistical analysis was done using Statistica® version 12. Means and 
standard deviations were used to describe continuous variables with normal distribution; 
and medians and ranges were used to describe continuous variables that were not normally 
distributed. Frequencies and proportions were used to describe categorical variables.  In 
comparing the susceptible to multi-drug resistant or survivors to non-survivors, the Student 
t-test was used when comparing parametric data, while Mann-Whitney U test was used to 
compare non-parametric data and the Pearson Chi-square test was used to compare 
categorical variables. Differences between the two groups were considered to be 
significant when the p-value was less than <0.05. 
 
3.0 RESULTS 
Between October 2007 and October 2011, of all patients admitted to the neonatal unit, 
there were 399 patients with Acinetobacter baumannii isolated from blood and/or CSF, 
resulting in an overall prevalence of 4.3 per 1000 live births and 2 per 1000 patient days. 
The prevalence remained relatively constant through the years, at 4.2, 5.0, 4.1, 4.2 and 3.8 
per 1000 live births and 1.9, 2.3, 2.0, 2.2 and 1.9 per 1000 patient days for 2007, 2008, 
2009, 2010 and 2011 respectively.  Acinetobacter baumannii accounted for 13% of the 
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3005 bacterial and fungal isolates (excluding those considered to be contaminants) 
identified over this 4 year period. Of the 399 Acinetobacter baumannii isolates, 379 had 
susceptibility data available for analysis (95%) and only 155 files could be retrieved for 
analysis of clinical data (39%). 
 
3.1 Baseline characteristics: 
Baseline maternal and neonatal characteristics are shown in Table 1. There were an equal 
number of males and females.  Ninety one percent (91%) of the infants were preterm, with 
a mean gestational age of 30.5 weeks. Of these, the majority (87%) was between 28 and 34 
weeks gestational age. The mean birth weight was 1401 grams, with 72% of the infants 
being very low birth weight. Thirty two percent of the patients were HIV exposed. The 
median age of onset of sepsis was 6 days. Twenty four percent (24%) of patients presented 
as early onset neonatal sepsis, that is within the first 3 days of life and the rest presented as 
late onset sepsis.  
 
Clinical presentation, laboratory findings at onset of infection and management 
interventions before onset of infection are summarized in Table 2. Thirty three percent of 
patients had received parenteral nutrition, and 36% had a central line in situ prior to the 
onset of infection. Nine percent of infants had surgery prior to the onset of infection. The 
most common clinical presentation at the time of assessment of infection was respiratory 
distress, followed by apneas, abdominal distension, increased gastric aspirates and 
hyperglycemia. Although majority of patients had a normal white cell count at the time of 
the sepsis screen, a high proportion of 29% were leucopenic (white cell count < 5 x 109/ 
L). Seventy three (47%) infants presented with thrombocytopenia (platelet count below 
150 x 109/L). Seventy eight (50%) infants had an elevated CRP (>10mg/L). Of the 155 
7 
 
babies, seventeen (11%) developed A. baumannii sepsis whilst on ventilator support. Of 
the remaining hundred and thirty eight (89%) patients, sixty (43%) required ventilation at 
the time of sepsis onset.  Forty five (29%) of the patients required some form of inotropic 
support. The mean duration of treatment was 8 days and the mean length of hospital stay 
was 29 days. The case fatality rate, which was defined as mortality within 7 days of onset 
of sepsis, attributable to Acinetobacter baumannii infection, was 32%. 
 
Table 1: Baseline characteristics and interventions before sepsis onset in neonates 
with positive blood or cerebrospinal fluid culture 
 
Variable n (%) 
Maternal HIV status 
Positive 
Negative 
Unknown 
 
49 (32) 
103 (66) 
3 (2) 
Gestational age 
<28 weeks 
28-34 weeks 
35-37 weeks 
>37 weeks 
Unknown 
 
29 (19) 
105 (68) 
6 (4) 
13 (8) 
2 (1) 
Birth weight 
<1000 grams 
1000-1499 grams 
1500-2499 grams 
≥2500 grams 
 
38 (24) 
74 (48) 
28 (18) 
15 (10) 
Male sex 83 (54) 
Median Apgar score at 1 minute  (IQR)* 7 (5-8) 
Median Apgar score at 5 minutes (IQR)* 9 (7-10) 
Interventions before sepsis onset 
Central venous access 
Parenteral nutrition 
Surgery 
 
56 (36) 
51 (33) 
14 (9) 
Receiving ventilator support at onset of sepsis 17 (11) 
                                  *IQR = Inter-quartile range: 25th – 75th percentile 
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Table 2. Clinical presentation and laboratory markers 
 
Variable n (%) 
Age at onset of sepsis 
Early-onset sepsis (onset ≤72 hours of life) 
Late-onset sepsis (onset >72 hours of life) 
 
37 (24) 
118 (76) 
Clinical presentation 
Respiratory distress 
Apnoea 
Abdominal distension 
Large gastric aspirates 
Hyperglycaemia 
 
34 (22) 
28 (18) 
26 (17) 
17 (11) 
12 (8) 
White cell count (x109/L) 
<5 
5.0 – 25.0 
>25 
Unknown 
 
45 (29) 
87 (56) 
11 (7) 
12 (8) 
Platelet count (x109/L 
<100 
100-150 
>150 
Unknown 
 
56 (36) 
17 (11) 
69 (45) 
13 (8) 
C-reactive protein (mg/L) 
<10 
10.0-20.0 
>20 
Unknown 
 
61 (40) 
14 (9) 
64 (41) 
16 (10) 
Normally sterile sites organism cultured from 
Blood only 
CSF only 
Blood and CSF 
 
145 (94) 
3 (2) 
7 (4) 
Number requiring mechanical ventilation* 60 (43) 
Number requiring inotropes 45 (29) 
Number died 49 (32) 
*Among babies who were not already on ventilator support (n=138) 
3.2 Antibiotic susceptibilities: 
Of the 399 isolates with Acinetobacter baumannii, 379 susceptibilities were available for 
review (Table 3 and 4). Two hundred and fourty two (64%) of the isolates were susceptible 
to Cephalosporins. Eighty one (21%) were sensitive to Aminoglycosides. Only 4% were 
sensitive to Carbapenems. Sixty four (17%) were resistant to multiple antibiotics (multi-
drug resistant - MDR) except to the Polymyxins namely Colistin. Over the four year period 
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the susceptibility of Acinetobacter baumannii to Cephalosporins was between 53 and 70%, 
and that to Aminoglycoside was 16-35% (Table 3).  Susceptibility to Piperacillin-
Tazobactam (Tazocin) declined over the years. Susceptibility to Ciprofloxacillin and 
Carbapenems increased over the years. The proportion of isolates that were MDR 
remained consistently high over the four year period ranging from 13 to 20%. Among 
those that were susceptible to the Cephalosporins, most were sensitive to Ceftazidime and 
among those that were susceptible to the Aminoglycosides most were sensitive to 
Tobramycin (Table 4).  
 
Table 3: Susceptibility of Acinetobacter baumannii to different groups of antibiotics 
 2007 
N=23 
2008 
N=105 
2009 
N=90 
2010 
N=91 
2011 
N=70 
TOTAL 
N=379 
 n (%) n (%) n (%) n (%) n (%) n (%) 
Cephalosporins 
- Sensitive 
- Resistant 
 
13 (57) 
10 (43) 
 
70 (67) 
35 (33) 
 
63 (70) 
27 (30) 
 
48 (53) 
43 (47) 
 
48 (69) 
22 (31) 
 
242 (64) 
137 (36) 
Aminoglycosides 
- Sensitive 
- Resistant 
 
8 (35) 
15 (65) 
 
26 (25) 
79 (75) 
 
14 (16) 
76 (84) 
 
20 (22) 
71 (78) 
 
13 (19) 
57 (81) 
 
81 (21) 
298 (79) 
Carbapenems 
- Sensitive 
- Resistant 
 
0 (0) 
23 (100) 
 
10 (10) 
95 (90) 
 
1 (1) 
89 (99) 
 
0 (0) 
91 (100) 
 
4 (6) 
66 (94) 
 
15 (4) 
364 (96) 
Piperacillin-
Tazobactam 
- Sensitive 
- Resistant 
 
 
1 (4) 
22 (96) 
 
 
17 (16) 
88 (84) 
 
 
3 (3) 
87 (97) 
 
 
2 (2) 
89 (98) 
 
 
1 (1) 
69 (99) 
 
 
24 (6) 
355 (94) 
Ciprofloxacillin 
- Sensitive 
- Resistant 
 
2 (9) 
21 (91) 
 
3 (3) 
102 (97) 
 
1 (1) 
89 (99) 
 
10 (11) 
81 (89) 
 
11 (16) 
59 (84) 
 
27 (7) 
352 (93) 
MDR  3 (13) 18 (17) 14 (16) 18 (20) 11 (16) 64 (17) 
Colistin 
- Sensitive 
- Resistant 
 
23 (100) 
0 
 
105 (100) 
0 
 
90 (100) 
0 
 
91 (100) 
0 
 
70 (100) 
0 
 
379 (100) 
0 
MDR – multi-drug resistant 
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Table 4: Susceptibility of Acinetobacter baumannii isolates to specific antibiotics. 
 2007 
N=23 
2008 
N=105 
2009 
N=90 
2010 
N=91 
2011 
N=70 
TOTAL 
N=379 
 n (%) n (%) n (%) n (%) n (%) n (%) 
Cephalosporins 
- Ceftazidime  
- Cefepime 
 
11 (48) 
13 (57) 
 
63 (60) 
63 (60) 
 
49 (54) 
57 (63) 
 
47 (52) 
14 (15) 
 
46 (66) 
13 ( (19) 
 
216 (57) 
160 (42) 
Aminoglycosides 
- Tobramycin 
- Amikacin 
- Gentamicin 
 
8 (35) 
0 (0) 
1 (4) 
 
20 (19) 
7 (67) 
1 (1) 
 
12 (13) 
4 (4) 
0 (0) 
 
16 (18) 
4 (4) 
0 (0) 
 
10 (14) 
4 (6) 
0 (0) 
 
66 (17) 
19 (5) 
2 (1) 
Carbapenems 
- Meropenem 
- Imipenem 
 
0 (0) 
0 (0) 
 
6 (6) 
5 (5) 
 
1 (1) 
0 (0) 
 
0 (0) 
0 (0) 
 
4 (6) 
1 (1) 
 
11 (3) 
6 (2) 
 
3.3 Characteristics of babies infected with susceptible isolates compared to those 
infected with multi-drug resistant isolates.  
Among the 155 files retrieved for analysis, susceptibility results were available for 153 
isolates. One hundred and thirty two patients (86%) were infected with susceptible isolates 
and 21 were infected with MDR isolates (14%). There were no significant differences in 
baseline characteristics between the 2 groups. Hyperglycemia was seen more frequently in 
the MDR group compared to the susceptible group (25% vs 5%; p=0.003). There were no 
cases of Acinetobacter baumannii meningitis in the MDR group, compared with 7% in the 
susceptible group (p=0.048). 
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Table 5. Comparing baseline characteristics and interventions before sepsis onset between 
susceptible and MDR isolates 
Variable Susceptible 
N = 132  
n  (%) 
MDR 
N = 21 
n  (%) 
p- 
value 
Maternal HIV status* 
Positive 
Negative 
 
40 (31) 
89 (69)      
 
8 (38) 
13 (62) 
0.52 
Gestational age* 
<28 weeks 
28-34 weeks 
35-37 weeks 
>37 weeks 
 
26 (20) 
88 (68) 
4 (3) 
12 (9) 
 
3 (14) 
15 (71) 
2 (10) 
1 (5) 
0.45 
Birth weight 
<1000 grams 
1000-1499 grams 
1500-2499 grams 
≥2500 grams 
 
32 (24) 
62 (47) 
25 (19) 
13 (10) 
 
5 (24) 
11 (52) 
3 (14) 
2 (10) 
0.95 
Male sex 70 (53) 11 (52) 0.96 
Median Apgar score at 1 minute (IQR) 7 (5-8) 5 (4-8) 0.05 
Median Apgar score at 5 minutes (IQR) 9 (4-10) 8 (5-10) 0.77 
Interventions before sepsis onset* 
Central venous access 
Parenteral nutrition 
Surgery 
 
44 (34) 
45 (35) 
13 (10) 
 
10 (48) 
6 (29) 
1 (5) 
 
0.22 
0.59 
0.45 
*Maternal HIV status and gestational age was unknown in 3 and 2 patients respectively; interventions before 
sepsis onset: central venous access- 2 for susceptible, parenteral nutrition- 2 for susceptible, surgery- 1 for 
susceptible 
 
3.4 Outcome 
Of the 155 cases, outcome data were available for 151 babies. There were 102 survivors 
and 49 deaths at 7 days after onset of infection. Case fatality rate was 32%. There were no 
statistically significant differences in case fatality rates between babies with MDR  
Acinetobacter baumannii (29%) and those with susceptible Acinetobacter baumannii 
(32%). 
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Table 6. Comparing clinical characteristics between susceptible and MDR isolates 
 
Variable Susceptible 
N = 132  
n  (%) 
MDR 
N = 21  
n (%) 
p- 
value 
Age at onset of sepsis 
Early-onset sepsis 
Late-onset sepsis 
 
28 (21) 
104 (79) 
 
7 (33) 
14 (67) 
0.22 
Clinical presentation* 
Respiratory distress 
Apnoea 
Abdominal distension 
Large gastric aspirates 
Hyperglycaemia 
 
27 (21) 
27 (21) 
24 (19) 
16 (12) 
7 (5) 
 
6 (30) 
1 (5) 
2 (10) 
1 (5) 
5 (25) 
 
0.36 
0.09 
0.35 
0.33 
0.003 
White cell count (x109/L)* 
<5 
5.0 – 25.0 
>25 
 
39 (32) 
77 (62) 
7 (6) 
 
6 (31) 
10 (53) 
3 (16) 
0.27 
 
Platelet count (x109/L)* 
<100 
100-150 
>150 
 
52 (43) 
14 (11) 
57 (46) 
 
4 (22) 
3 (17) 
11 (61) 
0.26 
C-reactive protein (mg/L)* 
<10 
10,0-20,0 
>20 
 
52 (44) 
11 (9) 
55 (47) 
 
9 (45) 
2 (10) 
9 (45) 
0.99 
Normally sterile site cultured 
Blood only 
CSF only 
Blood and CSF 
 
122 (93) 
7 (5) 
3 (2) 
 
21 (100) 
0 (0) 
0 (0) 
0.048 
Number requiring mechanical ventilation** 53 (45) 7 (39) 0.65 
Number requiring  inotropes 40 (30) 4 (19) 0.29 
Number died 41 (32) 6 (29) 0.75 
*Missing variables- Blood results: white cell count results-11 (9 susceptible, 2 MDR), platelets - 15 (12 
susceptible, 3 MDR); c-reactive protein – 15 (14 susceptible, 1MDR); outcome- 4 for susceptible; clinical 
presentation- 4 (3 susceptible, 1 MDR) 
**Among babies not already on ventilator support at time of sepsis (n=119 for susceptible; n=18 for MDR) 
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3.5 Comparison of characteristics between survivors and non-survivors  
Baseline characteristics were compared between patients that demised within 7 days of 
onset of sepsis and those that survived beyond 7 days of onset of sepsis. There were no 
significant differences in gestational age, birth weight, and HIV exposure. The median 5 
minute apgar score was significantly lower in the non-survivors (Table 7). There were 
significantly more babies with central venous lines prior to the onset of sepsis in the group 
that died compared to the group that survived (49% vs 31%; p=0.03). There were no 
statistical significant differences in white cell and platelet counts between survivors and 
non-survivors (Table 8). There was no significant difference in mortality between babies 
who developed sepsis while on ventilator support compared to the rest of the babies (41% 
vs 31%; p=0.41). In the group of babies who were not on a ventilator at the time of sepsis 
onset, a greater number among the babies who died required ventilator support (62% vs 
36%, p=0.005) compared to those who survived. Among the babies who died a greater 
number required inotropic support (57% vs 17%, p<0.001) compared to those who 
survived.  
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Table 7. Comparing baseline characteristics and interventions before sepsis onset between 
survivors and non-survivors 
Variable Survivors 
N = 102  
n  (%) 
Non-survivors 
N = 49  
n (%) 
p- 
value 
Maternal HIV status* 
Positive 
Negative 
 
31 (30) 
71 (70) 
 
17 (36) 
30 (64) 
0.48 
Gestational age* 
<28 weeks 
28-34 weeks 
35-37 weeks 
>37 weeks 
 
17 (17) 
69 (68) 
5 (5) 
10 (10) 
 
11 (23) 
34 (71) 
1 (2) 
2 (4) 
0.45 
 
 
 
 
Birth weight 
<1000 grams 
1000-1499 grams 
1500-2499 grams 
≥2500 grams 
 
20 (20) 
49 (48) 
21 (21) 
12 (12) 
 
18 (37) 
23 (47) 
6 (12) 
2 (4) 
0.06 
Male sex 55 (54) 28 (57) 0.71 
Median Apgar score at 1 
minute  (IQR) 
 
7 (5-8) 
 
6 (5-8) 
 
0.19 
Median Apgar score at 5 
minutes 
(IQR) 
 
9 (8-10) 
 
8 (7-9) 
 
0.02 
Interventions before sepsis 
onset* 
Central venous access 
Parenteral nutrition 
Surgery 
 
 
31 (31) 
32 (32) 
10 (10) 
 
 
24 (49) 
16 (33) 
3 (6) 
 
 
0.03 
0.9 
0.45 
*Missing variables- 2 for maternal HIV status among the non-survivors and 2 for gestational age (1 among 
the survivors and 1 among the non-survivors); interventions before sepsis onset: central venous access- 1 for 
survivors, parenteral nutrition- 1 for survivors 
 
 
15 
 
Table 8. Comparing clinical characteristics between survivors and non-survivors 
 
Variable Survivors 
N = 90  
n (%) 
Non-survivors 
N = 49 (%) 
n (%) 
p- 
value 
Age at onset of sepsis 
Early-onset sepsis 
Late-onset sepsis 
 
24 (24) 
78 (76) 
 
13 (27) 
36 (73) 
0.69 
Clinical presentation* 
Respiratory distress 
Apnoea 
Abdominal distension 
Large gastric aspirates 
Hyperglycaemia 
 
25 (26) 
15 (15) 
21 (21) 
13 (13) 
7 (7) 
 
8 (16) 
12 (24) 
4 (8) 
3 (6) 
5 (10) 
 
0.21 
0.18 
0.04 
0.19 
0.52 
White cell count (x109/L)* 
<5 
5.0 – 25.0 
>25 
 
27 (28) 
62 (65) 
7 (7) 
 
17 (40) 
23 (53) 
3 (7) 
0.4 
Platelet count (x109/L)* 
<100 
100-150 
>150 
 
33 (35) 
11 (12) 
50 (53) 
 
22 (50) 
6 (14) 
16 (36) 
0.17 
C-reactive protein (mg/L)* 
<10 
10.0-20.0 
>20 
 
48 (48) 
9 (9) 
42 (42) 
 
11 (30) 
5 (13) 
21 (57) 
0.14 
Normally sterile site cultured 
Blood only 
CSF only 
Blood and CSF 
 
96 (94) 
2 (2) 
4 (4) 
 
45 (92) 
1 (2) 
3 (6) 
0.84 
Number requiring  mechanical 
ventilation** 
33 (36) 26 (62) 0.005 
Number requiring  inotropes 17 (17) 28 (57) <0.001 
Multi-drug resistant 15 (15) 6 (13) 0.75 
*Missing variables – white cell count- 12 (6 –survivors, 6- non-survivors), platelet count – 13 (8- survivors, 
5- non-survivors), c-reactive protein – 15 (survivors-3, non-survivors-12), ); clinical presentation – 4 for 
survivors.  
** Among babies not already on ventilator support at time of sepsis (n=92 for survivors; n=42 for non-
survivors) 
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4.0 Discussion 
This study reports on some of the epidemiologic features of infections caused by 
Acinetobacter baumannii in a neonatal unit from a tertiary public government hospital. It  
reports on the prevalence and proportion of patients infected with Acinetobacter 
baumannii,  clinical characteristics of affected patients, the antimicrobial susceptibility 
patterns, outcomes, and comparison of patient characteristics between those with multi-
drug resistant and susceptible Acinetobacter baumannii, and between those who died and 
those who survived.  
 
The findings in this study are that from October 2007 to October 2011, the prevalence of 
Acinetobacter baumannii was 4.3 per 1000 live births and 2 per 1000 patient days; 
Acinetobacter accounted for 13% of bacterial and fungal isolates from normally sterile 
sites of infants admitted to the neonatal unit; majority of infants infected with this bacteria 
are born preterm and are very low birth weight infants; more than a third of infants were on 
parenteral nutrition and had central venous line in situ prior to the time of diagnosis of 
infection. A significant number of isolates (17%) are multi-drug resistant, only being 
sensitive to Colistin. While susceptibility has remained the same over this four year period 
for Cephalosporins and Aminoglycosides, it improved slightly for Carbepenems. It has a 
high case fatality rate. There were no significant statistically differences between infants 
infected with susceptible and MDR pathogens in demographic characteristics, laboratory 
findings and mortality, except that more babies in the MDR group presented with 
hyperglycemia at onset of sepsis and no babies in this group had CSF involvement. In 
comparing the survivors and non-survivors the factors associated with mortality were prior 
use of a central venous line, need for mechanical ventilation and need for inotropes.   
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This prevalence of Acinetobacter baumannii infection among bacterial and fungal isolates 
is high compared to the reported prevalence in other neonatal intensive care units from 
previous studies, ranging from 0.2 – 14.1%. 8, 24, 25, 26 However, the prevalence is lower than 
the reported prevalence of 21% in a recent South African study. 27 In addition, the 
incidence of 2 cases per 1000 patient days that we have reported is higher than that of 0.5 
per 1000 patient days reported in a recent study. 28 Preterm and very low birth weight 
infants were mostly affected, in keeping with previous studies looking at associated risk 
factors. 12, 13, 26 Use of total parenteral nutrition and central venous lines prior to the onset 
of sepsis was high, at 33% and 36% respectively. The use of central venous catheters has 
been shown in previous studies to be associated with an increased risk of Acinetobacter 
baumannii infection. 12, 13, 26 Although 76% of infections were acquired after 3 days of life, 
it is of concern that 24% of the time, the infection was acquired before 72 hours suggesting 
maternal acquisition. This suggests the high virulence of the organism in a very vulnerable 
host population.  In a retrospective study conducted in India, Acinetobacter baumannii 
accounted for 14.4% of early onset neonatal sepsis. 29 In this study, the most common 
affected system at the onset of infection was the respiratory system (respiratory distress 
and apneas), followed by gastrointestinal tract (abdominal distension and aspirates). Of 
note, is that a high proportion of the patients required mechanical ventilation (43%) and 
inotropic support (29%) suggesting severity of sepsis associated with this organism. 
Laboratory markers of infection that were suggestive of sepsis in these patients included a 
high mean CRP, leukopenia and thrombocytopenia. 
 
The degree of multi-drug resistance of the Acinetobacter baumannii isolates is very 
concerning, with 17% of isolates being only sensitive to Colimycin. The majority of 
isolates were sensitive to Cephalosporins or Aminoglycosides. Carbapenem resistance was 
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high. Resistance patterns remained mostly unchanged over the years. Most of the isolates 
are still susceptible to Cephalosporins compared to other groups of antimicrobials. 
Carbapenem susceptibility improved slightly. Piperacillin-Tazobactam susceptibility has 
declined over the years. The increase in susceptibility to Ciprofloxacillin is of concern as 
this may imply increasing resistance to other agents. The rates of multi-drug resistance 
remained consistently high over the years. High rates of multi-drug resistance have been 
shown in many studies. 11, 12, 13, 14, 22 A recent South African study has also demonstrated a 
high rate of multi-drug resistance among Acinetobacter baumannii isolates.27These 
findings highlight the need for proper infection control and antibiotic stewardship 
practices. Infection control measures should focus on hand hygiene and adherence to other 
infection prevention and control (IPC) guidelines. Enforcement of continuing antibiotic 
stewardship practices will prevent selection of resistant strains of Acinetobacter 
baumannii, and hence reduce the prevalence of multi-drug resistance. These practices 
include early discontinuation of empiric antibiotic therapy and appropriate use and 
duration of antibiotics in blood culture confirmed infections. Regular IPC audits should be 
carried out in the unit, feedback should be given to the unit and measures to improve 
infection control and antibiotic stewardship practices should be implemented accordingly. 
 
Surprisingly, there were no significant differences between the baseline characteristics and 
mortality of patients with multi-drug resistant and susceptible Acinetobacter baumannii. 
This is not in keeping with other studies which have shown a strong association between 
mortality and multi-drug resistant Acinetobacter baumannii. 12, 26  
 
Mortality attributable to Acinetobacter baumannii sepsis was high, at 32%, higher than the 
reported mortality of 22% from a previous South African study. 19 The reported mortality 
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rates from other studies range from 14% - 80%. 12, 13, 23, 26 Comparing baseline 
characteristics of survivors to non-survivors, not surprisingly, the need for mechanical 
ventilation and inotropic support was significantly higher in babies that died, suggesting 
that this was a sicker group of infants who in most instances required ventilator and 
inotropic support, most likely secondary to septic shock, prior to their demise. But this also 
highlights the need for ventilator and inotropic support as a poor prognostic sign for 
favourable outcome. In addition, more babies who died had a central venous line 
placement compared to babies that survived. The presence of central venous lines has been 
shown to increase the risk of Acinetobacter infection, but as far as we know, has not been 
shown to be associated with increased mortality. 
 
This study has several limitations. This was a retrospective record review. Although 
susceptibility patterns could be retrieved on majority of the cases (95%), only 39% of the 
hospital files could be retrieved for analysis. Of these, outcome data were not available for 
3% of cases. Although the sample size is small, to our knowledge, this study represents one 
of the largest number of studied patients with Acinetobacter baumannii sepsis. In view of 
the retrospective nature of the study, it is possible that the prevalence of Acinetobacter 
baumannii infection in the unit is not a true reflection of the actual prevalence as adequate 
blood cultures may not have been taken at the onset of suspected sepsis, and that could 
contribute to a lower yield.  
 
In conclusion, the prevalence and proportion of infections due to Acinetobacter baumannii 
in the unit is high. Of major concern is the high rate of multi-drug resistance as well as 
case fatality.  Our findings highlight the need for strict enforcement of infection control 
and antibiotic stewardship practices. Factors that contribute to breech of infection control 
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practices in developing countries, such as overcrowding of nurseries and staff shortages 
need to be urgently attended to. This study also highlights the need for continuous 
surveillance programs as well as the need for ongoing research, preferably prospective in 
nature, on nosocomial infections, resistance patterns as well as interventions aimed at 
improving infections in neonatal ICUs especially in developing countries. 
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6.0 APPENDICES 
6.1 APPENDIX A: 
PROTOCOL 
Background 
Neonatal Mortality rates in developing countries has been reported to be as high as 40-50 
per 1000 live births.1 Of these, infections are one of the major killers, accounting for up to 
56% of hospital deaths.2 In South Africa perinatal conditions account for up to 31% of 
infant mortality rates, of which 7% have been attributed to infections.3 Infections in 
neonates can either be acquired from the mother or from the hospital. Organisms causing 
infections within the first 72 hours of life is often acquired from the mother. Neonatal 
nosocomial infections refer to infections in the newborn that are hospital-acquired and 
usually occurring after the first 72 hours of life.4 Premature neonates are at high risk of 
infection due to their underdeveloped innate immunity, fragile skin and lack of protective 
maternal antibodies. The increasing survival rate of these premature babies in neonatal 
units has led to an increase in duration of hospital stay, rendering them more susceptible to 
nosocomial infections.  
 
The National Institutes of Child Health and Human Development (NICHD) Neonatal 
Research Network reported on a cohort of 6215 very-low-birth-weight infants (401-1500 
grams).5 Twenty-one percent (21%) of these infants developed late-onset neonatal sepsis, 
of which 18% were caused by gram-negative organisms. Infection was inversely 
proportional to birth weight and gestational age. Infants who developed late-onset neonatal 
sepsis were found to have prolonged hospital stay. Overall mortality was reported to be as 
high as 18%, especially in babies infected with gram-negative organisms. Other studies 
have quoted the incidence of nosocomial infections ranging from 7%-24%.5, 6, 7 
 
In a recent 
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large cohort study of babies admitted to a neonatal intensive care unit, 14.2% developed 
late-onset neonatal sepsis, with an overall mortality of 12.6%. Gram negative sepsis 
accounted for 10.4% of the sepsis attributable mortality.8 Nosocomial infections has been 
also shown to increase the risk of neuro-developmental and growth impairment.9, 10   
Among the gram-negative bacterial organisms causing infections, Acinetobacter 
baumannii has recently emerged as a leading nosocomial pathogen responsible for 
numerous hospital outbreaks over the past decade.11, 12, 13   In a recent cohort, gram negative 
bacilli accounted for 32.6% of the late-onset neonatal infections, of which Acinetobacter 
baumannii accounted for 4.2%.8 Acinetobacter baumannii are aerobic gram-negative 
cocco-bacilli, belonging to the larger family of Acinetobacter species.19   These organisms 
have been recovered from soil, water, animals and humans. They are normal inhabitants of 
human skin, which in turn could be the major source of severe infections.14 In addition, 
various studies have shown the ability of Acinetobacter baumannii to survive in the 
hospital environment for prolonged periods, potentially playing a role in transmission of 
the organism during outbreaks. Sources have been shown to include reusable medical 
equipment, mattresses and gloves.15, 16, 17, 18 
 
The main concern with Acinetobacter baumannii is its ability to accumulate mechanisms of 
antimicrobial resistance rapidly, leading to multi-drug resistance. Acinetobacter baumannii 
has been shown to have acquired resistance to various classes of antimicrobials including 
Penicillin’s, Aminoglycosides, first, second and third generation Cephalosporin’s and more 
recently, Fluoroquinolones and Carbapenems. The Polymyxins (Colistimethate sodium/ 
Colistin) are the only agents with the overall highest susceptibility rates.12, 13, 20, 21, 22  The 
most common mechanism of resistance to β-lactam antibiotics is the ability of the 
organism to produce β-lactamases. Other mechanisms of resistance include chromosomal 
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mutations as well as loss of specific outer membrane proteins responsible for influx of 
antibiotics into the cell.19  
The main sites of infection include the respiratory tract, urinary tract, bloodstream, wounds 
and burns.21 Risk factors identified for the development of Acinetobacter baumannii 
infection include prematurity, very-low-birth-weight, age < 7 days, prolonged hospital stay 
> 7 days, mechanical ventilation, use of central venous catheters, as well as prior broad 
spectrum antibiotic use.12, 13 The mortality rates associated with Acinetobacter baumannii 
infections in neonates ranges from 14%-80%. 12, 13, 23 A South African study reported a 
mortality of 22% .18 
 
In our neonatal unit at Chris Hani Baragwanath Academic Hospital (CHBAH), limitations 
in resources, overcrowding and the lack of isolation facilities leading to nosocomial 
infections are a major problem. We have seen an increase in numbers of Acinetobacter 
baumannii as a cause of infection in our neonates over the past years both as an endemic 
organism as well as a cause of outbreaks. The mortality due to Acinetobacter baumannii 
seems to vary during the different outbreaks and reasons for this are not clear. Possible 
reasons for this variation in mortality might include changes in antibiotic susceptibility, 
severity of illness or virulence of the organism and underlying problems in the infected 
patients. Therefore we would like to determine characteristics of patients who are infected 
with this organism, antibiotic susceptibilities of this organism and compare the 
characteristics of survivors to non-survivors.  
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Objectives 
1. To determine the incidence of sterile sites (blood and cerebrospinal fluid) infections 
due to Acinetobacter baumannii infection in infants admitted to CHBAH neonatal 
unit 
2.  To determine antibiotic susceptibilities of Acinetobacter baumannii isolated from 
normally sterile sites.  
3. To describe the characteristics of infants  infected with Acinetobacter baumannii 
4. To determine the mortality rates and factors associated with mortality in infants 
infected with Acinetobacter baumannii.  
 
Justification 
1) This study will give us an idea of the burden of Acinetobacter baumannii sepsis in our 
neonatal unit. 
2) By describing characteristics of infants who are more likely to die from Acinetobacter 
baumannii infection in our population of babies, we can have a higher index of 
suspicion for poor outcome and therefore encouraging early empiric treatment that 
includes coverage for Acinetobacter baumannii. Doing this might reduce the mortality 
rate due to this infection. 
3) The results of this study will encourage the enforcement and improvement of infection 
control measures among staff at CHBAH. 
4) This study will provide us with a basis for future randomized control trials and 
interventional studies involving infection control strategies. 
 
Methods 
Study design: This will be a retrospective descriptive study.   
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Study population: It will include all babies admitted in the neonatal unit at CHBAH from 
1st October 2007 to 31st October 2012, who were infected with A. baumannii.  
Study procedures and data collection: Names of babies will be obtained from the 
microbiology department database. Hospital bed-letters of these babies will be retrieved 
from the department filing room. Data obtained from these bed-letters will be entered into 
a data collection sheet (see attached) and thereafter into a computerized database and 
analyzed. Information that will be analyzed will include prenatal factors such as patient 
demographics and maternal HIV status. Postnatal factors obtained will include age and 
weight of the baby at the onset of Acinetobacter baumannii sepsis, use of central venous 
catheters, urinary catheters, antibiotic use prior to the onset of sepsis, any surgical/ invasive 
procedures, use of total parenteral nutrition, baby’s HIV exposure and status if available, 
need for mechanical ventilation, duration of ventilation, need for inotropic support, length 
of hospital stay as well as death or survival to discharge. A case of Acinetobacter 
baumannii sepsis will be defined as a neonate with confirmed culture positive with 
Acinetobacter baumannii from one or more normally sterile sites. Sterile sites will include 
blood, and cerebrospinal fluid. Multiple blood cultures yielding the same organism from 
the same patient within 72 hours of each other will be considered to be a single infection. 
The antibiotic susceptibilities of Acinetobacter baumannii isolates will be retrieved from 
the laboratory database. Acinetobacter baumannii will be defined as pan-resistant when the 
organism is resistant to all antibiotics except the Polymyxins. Clinical presentation at the 
time of developing the sepsis as well as laboratory markers of infection will be collected 
for review. Laboratory markers of infection will include white cell counts, including 
differential counts, platelet counts, C-reactive protein and cerebrospinal fluid (CSF) 
results. Patient’s demographics, clinical presentation, laboratory markers and antibiotic 
susceptibilities will be compared between those who died and those who survived. 
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Statistical Analysis 
Information collected using the data collection sheet will be analyzed. Means, medians and 
ranges will be used to describe continuous variables. Frequencies and proportions will be 
used describe categorical variables.  Student t-test and chi-square test will be used to 
compare continuous and dichotomous variables, respectively between survivors and non-
survivors. 
 
Ethics 
The approval for conducting this study will been obtained from the University of 
Witwatersrand Human Research Ethics Committee (HREC), the Hospital Superintendent 
and the Head of Department of Paediatrics at Chris Hani Baragwanath Academic Hospital. 
Though names of patients will be used when retrieving the charts, no names of patients or 
identifiers will be used as part of the data to be collected. All patients will be given study 
numbers in order to maintain confidentiality. 
 
Timing 
I will begin the study as soon as the proposal has been accepted and intend completing it 
within 6 months. 
 
Funding 
No funding will be required. All necessary expenses for paper and printing will be self-
funded. 
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